Raheleh Roudi

Sep 15, 2023 | frontiersin.org | Andreas Behren |Raheleh Roudi |Hongwei Cheng

1 IntroductionGastric cancer (GC) is the fifth most common cancer and the fourth leading cause of cancer-related mortality in the world (1). Although fluoropyrimidines and platinum-based chemotherapy as first-line therapy and taxanes plus ramucirumab as second-line therapy are standard treatment for GC, prognosis remains poor and median survival is approximately one year (2–5).